The Cross-Border Biotech Blog

Biotechnology, Health and Business in Canada, the United States and Worldwide

About the Authors

Editor

Jeremy Grushcow is a partner at Norton Rose Canada. Jeremy has a Ph.D. in Molecular Genetics and Cell Biology, and is a member of the Bar in Ontario, New York and Illinois. His practice focuses on life science and technology companies. He has represented private equity firms, investment banks, operating companies and founders in connection with public and private offerings, mergers and acquisitions, joint ventures and other strategic transactions, licensing and outsourcing agreements, operating and service agreements and ongoing disclosure advice. Prior to joining Norton Rose, Jeremy practised in the area of intellectual property transactions at Kirkland & Ellis LLP and in capital markets at Shearman & Sterling LLP. LinkedIn Profile; Norton Rose Bio. Send email. Posts by Jeremy.

Contributors

Dan Case is currently finishing his PhD in Neuroscience at McMaster University in Hamilton, Ontario, and is also an intern working in science diligence at Bloom Burton & Co., Canada’s largest health care-specialized investment firm. Dan completed his BSc in biological sciences at the University of Alberta, and his doctoral work at McMaster focused on understanding the formation of neural circuits in the developing brain. Send email. Posts by Dan.

Jacob Cawker is an associate at Norton Rose, and is part of our Life Sciences transactional team. He has an Honours Bachelor of Science from the University of Toronto at Mississauga with a specialist in Psychology and a particular interest in neuroscience, and he worked in a behaviour genetics lab at the University of Toronto before entering law school at Osgoode Hall University. Send email. Posts by Jacob.

Christian Hartmann has worked for the past 3.5 years at Deloitte Canada as an Account Manager supporting the National Life Sciences and Mining Practices. He has worked on large pharmaceutical accounts and works to develop relationships with early stage biotechnology companies. He also represents Deloitte at key industry events including BioFinance and BIO. Christian received his diploma in Biotechnology from Seneca College and has worked in industry as part of the team that developed an early detection kit for Myocardial Infarction at Spectral Diagnostics. He has also owned and operated a business in the Health Food industry gaining approvals from Health Canada, FDA, CRA and CITIES  to import and distribute a novel plant based supplement product for sale in Canada and the U.S.

John Holyoake is a scientific diligence associate at Bloom Burton & Co., Canada’s leading healthcare-specialized investment banking firm. At Bloom Burton, John conducts technical diligence on healthcare companies and advises client companies on their M&A and development strategies. John completed his PhD in the Department of Biochemistry at the University of Oxford in 2007 before continuing his research as a postdoctoral research fellow cross-appointed between the Hospital for Sick Children and the University Health Network in Toronto. Alongside his research experience, John has worked with biopharmaceutical and life science consulting companies, as well as being involved with several seed-stage companies focused on the application of computational methods to drug discovery. Send email. Posts by John.

Dani Peters is a Canadian who works for a Washington, D.C. government affairs firm but is based in Toronto. She is specialized in helping life science and environment technology companies access the U.S. government for funding, but is also involved in a variety of healthcare-related legislation, including patent reform and follow-on biologics. Dani’s firm, Fabiani & Company assists its clients in obtaining U.S. government funding/ contracts in defence/intelligence, homeland security, environment technology and biotechnology. The company also represents clients before the U.S. Congress and Executive Branch on a wide variety of policy areas. Send email. Posts by Dani.

Beni Rovinski is a Managing Director at Lumira Capital. Beni’s investment focus has primarily been on Canadian and US mid- to late-stage private and public companies involved in drug discovery and development, biological and small molecule therapeutics, drug delivery, specialty pharmaceuticals, genomics, proteomics and diagnostic devices. Lumira BioPosts by Beni.

Wayne Scharr is a semi-retired healthcare consultant with over thirty years of experience in the biopharmaceutical and financial sectors. He initially worked in the old biotechnology industry isolating biologicals from animal tissues and human blood. After a stint as a lobbyist for the Canadian generic drug industry, he moved to the financial sector in 1992. He has been an analyst for four independent investment banks, interspersed between time with biotechnology companies, venture capital and investor relations. He has a Ph.D in Chemistry from Queen’s University (Kingston) and an MBA from York University (Toronto). Send email. Posts by Wayne.

Peter van der Velden is the President and CEO of Lumira Capital.  Lumira BioPosts by Peter.

Steven Zuccarelli is an articling student at Norton Rose. Prior to attending Osgoode Hall Law School, Steven received an Honours Bachelor of Science and a Master of Science from McMaster University, with particular emphasis on infection, immunity and immunological mechanisms of allergic disease.

Past Contributors


Richard Chan was a science consultant at R&D Funding Management. He now works at Deloitte. His interests lie in promoting the life science and biotech industries in Canada.  Richard has a Ph.D. specializing in molecular biology and biotechnology. More recently, he was a postdoctoral research fellow working on cancer signaling and proteomics projects at both Beth Israel Deaconess Medical Center/Harvard Medical School in Boston and at the Ontario Cancer Institute in Toronto.  LinkedIn ProfileEmail RichardPosts by Richard.

Audrey Fried was the blog’s copy editor as well as an occasional contributor focusing on case law of interest to the cross-border biotech community.  Audrey is a U.S.-trained lawyer and mediator.  After law school, Audrey clerked for Judge William J. Bauer on the Seventh Circuit Court of Appeals and practiced in the area of complex commercial litigation for several years at Mayer Brown LLP before turning her attention to conflict resolution and social media.  Send emailPosts by Audrey.

Mark Curtis was an associate at the Vanscia Group, a consulting firm focused on the commercialization of university-stage life science innovations in North America and abroad, and he worked as a consultant to Bloom Burton & Co., a boutique investment bank in Toronto that focuses exclusively on the biotechnology and healthcare industries. Mark is currently working in the mining and resources sector. Prior to this he was involved in stem cell research at the Ontario Cancer Institute. Mark completed a Bachelor of Science degree in biology at Queen’s University and a Master’s degree in biotechnology, with a specialization in stem cell biology, at the University of New South Wales in Sydney, Australia. Send emailPosts by Mark.

Follow

Get every new post delivered to your Inbox.

Join 130 other followers